News
USA patents for pest control compositions secured
24 April 2014
TyraTech, Inc. (AIM: TYR and TYRU), a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce that the Company has received notice from the United States Patent and Trademark Office ("USPTO") granting two new patents for the Company's novel pest control compositions.
The first patent covers a range of current and pipeline animal health products, including those that will be sold by Novartis Animal Health US, Inc. for the control of flies, cockroaches and other insects in production animal facilities and premises. This patent also covers products sold into the professional pest control and commercial/institutional markets by Envance Technologies, LLC, which is TyraTech's joint venture with AMVAC Chemical Corporation. The patent has a 20-year term, which expires in 2027.
The second patent covers TyraTech's Extend™ technology, which harnesses the synergy between natural and synthetic compounds to achieve increased efficacy while reducing the environmental footprint of synthetic pesticides. This patent supports a number of the Company's animal health pipeline products, as well as pipeline products from Envance Technologies. The patent has a 20-year term, which expires in 2029.
The issuance of these patents raises TyraTech's patent portfolio to 21 granted United States and international patents protecting its proprietary screening platform and compositions. The Company currently has 50 United States and international patent applications pending.
Bruno Jactel, Chief Executive Officer, said: "These new patents are a testimony to the quality and innovation behind TyraTech's technology and products. More importantly they will provide protection for TyraTech's products that are already in the market and for products that TyraTech is currently developing. Our research and development teams are continually working to develop new products and formulations that are patentable with the objective of strengthening our growth platform."
For further information please contact:
| TyraTech Inc. Alan Reade, Non-Executive Chairman Bruno Jactel, Chief Executive Officer |
Tel: +44 7841978709 Tel: +1 919 415 4340 |
| SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady |
Tel: +44203 368 3551 |
| Allenby Capital Limited , Joint Broker Chris Crawford |
Tel: +44 20 3328 5656 |
| Whitman Howard Limited, Joint Broker Ranald Mc-Gregor Smith / Niall Devins |
Tel: +44 20 7087 4550 |
| Walbrook, Financial PR and IR Bob Huxford /Guy McDougall (Public Relations) Paul Cornelius (Investor Relations) |
Tel: +44 20 7933 8792 Tel: +44 20 7933 8794 |
Disclaimer for U.S. Site Visitors
This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.